99mTc-labelled rituximab, a new non-Hodgkinʼs lymphoma imaging agent: first clinical experience

ObjectiveThis study was performed to explore the possibility of using 99mTc-rituximab as an imaging agent to assess expression of CD20 antigen in patients with B-cell non-Hodgkin's lymphoma (NHL) before (radio) immunotherapy, for staging and subsequent evaluation of remission of NHL.MethodsRituximab